3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
28
Lymphoma
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Breast Neoplasms
22
Multiple Myeloma
21
Lymphoma, Large B-Cell, Diffuse
21
Carcinoma, Non-Small-Cell Lung
21
Lymphoma, Non-Hodgkin
19
Lymphoma, Mantle-Cell
17
Lymphoma, Follicular
16
Hodgkin Disease
15
Lymphoma, T-Cell, Cutaneous
13
Glioblastoma
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Brain Neoplasms
12
Recurrence
11
Myelodysplastic Syndromes
11
Mycosis Fungoides
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia
11
Burkitt Lymphoma
11
Neuroblastoma
10
Neoplasms
10
Sezary Syndrome
9
Congenital Abnormalities
9
Prostatic Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
8
Squamous Cell Carcinoma of Head and Neck
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms, Plasma Cell
7
Interventions
Rituximab
9
Cyclophosphamide
8
fludarabine
5
dacetuzumab
5
blinatumomab
5
Brentuximab Vedotin
4
Bendamustine Hydrochloride
4
ibrutinib
3
fludarabine phosphate
3
Vincristine
3
Prednisone
3
Melphalan
3
Etoposide
3
Doxorubicin
3
tetulomab tetraxetan lu-177
2
ponatinib
2
cobomarsen
2
acalabrutinib
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Lutetium
2
Ifosfamide
2
Everolimus
2
Cytarabine
2
Carboplatin
2
Busulfan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphatic Diseases
×
Vorinostat
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts